Recently, “Johnson & Johnson China” has been exposed to layoffs, with compensation packages varying as “N+1,” “N+2,” and “N+3.” An employee who was laid off revealed that the layoff scale is 20%, mainly involving the surgical department.
According to a report by Nan Du Bay Financial and Social on November 15, employees from Johnson & Johnson China who were laid off disclosed that the layoff scale is 20%, primarily affecting the surgical department. Layoff notices were sent to individuals via email, and the departure date she signed was the end of this year. In recent years, Johnson & Johnson has had ongoing personnel changes, but this time it involves structural adjustments with a wider impact. The compensation is said to be quite good, divided based on years of service, with a maximum of “N+3.”
Recent rumors suggest that “Johnson & Johnson China” has reorganized its surgical business unit’s organizational structure. It’s reported that starting from January 1, 2025, the surgical business unit will be restructured into six departments: Minimally Invasive and Energy Surgical Business Unit, Wound Closure Business Unit, Biomedical Surgical Business Unit, Surgical Full Product Expansion Business Unit (namely the Broad Market Business Unit), Strategic Market Department, and Robotics and Digitalization.
The report by Nan Du Bay Financial and Social states that the interviewed employee confirmed these developments.
On November 14, a Nan Du Bay Financial and Social reporter reached out to “Johnson & Johnson China” through official email channels but had not received a response by the time of publication. On the same day, the reporter called “Johnson & Johnson China” but did not receive a clear response.
Public records show that since 2023, Johnson & Johnson has faced multiple layoffs, involving business mergers, the closure of its cardiovascular and metabolism departments, and the dismissal of employees from its subsidiary located in a factory in the United States. However, Johnson & Johnson has not publicly responded to these incidents in the media.
The American Johnson & Johnson group (J&J) originally owned brands like Da Bao, Johnson’s Baby, Listerine, Tylenol, Band-Aid, Neutrogena, and Acuvue, covering products in personal care and healthcare. In 2021, the group split its consumer health business, focusing on two main sectors: Medical Technology (MedTech) and Innovative Medicine. The consumer health business became an independent company named Kenvue and was listed on the NYSE in 2023.